Results 21 to 30 of about 128,993 (222)
Background Biologic drugs such as adalimumab, etanercept, and infliximab represent major first-line and second-line treatments for rheumatoid arthritis (RA) patients. However, their high cost poses a massive burden on healthcare systems worldwide.
Bruna O. Ascef +6 more
doaj +1 more source
Background/Aims: Current knowledge and viewpoints regarding biosimilars among physicians in Asia are unknown, even though these were investigated by European Crohn’s and Colitis Organization (ECCO) members in 2013 and 2015.
Soo-Kyung Park +4 more
doaj +1 more source
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? [PDF]
Biological medicines contain a biological substance that is produced by or derived from a living organism. The active substances of biologicals are usually larger and more complex than those of chemically derived medicines (non-biological medicine). Biologicals are used for the treatment of chronic and life-threatening diseases such as cancer, multiple
Farfan-Portet, María-Isabel +4 more
openaire +2 more sources
Background Infliximab (IFX) has changed the management of many life-threatening immune-mediated diseases. The high cost of IFX and its patent expiry have led to pharmaceutical companies developing a biosimilar; however, its safety profile remains unknown
Iku Niinomi +6 more
doaj +1 more source
Background In Norway, an annual tender system for the prescription of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) has been used since 2007. This study aimed to explore annual b/tsDMARDs costs and disease outcomes in
Alen Brkic +10 more
doaj +1 more source
Slow uptake of biosimilars in some regions is often attributed to a lack of knowledge combined with concerns about safety and efficacy. To alleviate physician and patient apprehensions, regulatory reviews from four major regulatory authorities (RAs ...
Beverly Ingram +3 more
doaj +1 more source
Generics, Biosimilars, and the Ethics of Pricing Pharmaceuticals [PDF]
Recent price hikes by pharmaceutical companies underscore the importance of competition in an industry that often sets prices according to what the market will bear. A steady pipeline of generics and biosimilars is the surest check to the rising prices of drugs and biologics.
openaire +1 more source
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data [PDF]
In 2006, the European Medicines Agency (EMA) approved Omnitrope(®) as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin(®), Pfizer).
Zabransky, Markus +11 more
core +1 more source
Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS [PDF]
Therapeutic monoclonal antibodies (mAbs) have made a tremendous impact in treating patients with various diseases. MAbs are designed to specifically target a cell and illicit a response from the immune system to destroy the cell. As originator mAb drug patents are coming to an end, generic pharmaceutical companies are poised to replicate and produce so-
Kerry M, Wooding +2 more
openaire +2 more sources
Purification Process of a Recombinant Human Follicle Stimulating Hormone Biosimilar (Primapur®) to Yield a Pharmaceutical Product with High Batch-to-Batch Consistency [PDF]
Recombinant human follicle stimulating hormone (r-hFSH) is widely used for infertility treatment and is subject to the development of biosimilars. There are different purification strategies that can yield r-hFSH of pharmaceutical quality from Chinese hamster ovary cell culture broth.
Maria Sinegubova +6 more
openaire +3 more sources

